Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

SymBio Pharmaceuticals Ltd (4582)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
175.0 -5.0    -2.79%
06:59:22 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 387,700
  • Bid/Ask: 174.0 / 176.0
  • Day's Range: 173.0 - 181.0
Type:  Equity
Market:  Japan
ISIN:  JP3383050006 
SymBio Pharmaceuticals 175.0 -5.0 -2.79%

SymBio Pharmaceuticals Company Profile

 
Read the SymBio Pharmaceuticals Ltd company profile to learn more about the business and the management team. View SymBio Pharmaceuticals Ltd facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

122

Equity Type

ORD

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trial in combination with AZA to treat HR-MDS. In addition, it is involved in the development SyB V-1901, an antiviral drug. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

Contact Information

Address Toranomon 30 Mori Building 3-2-2 Toranomon
Minato-ku Tokyo, 105-0001
Japan
Phone 81 3 5472 1125
Fax 81 3 5472 3054

Top Executives

Name Age Since Title
Fuminori Yoshida 72 2005 CEO, President, Corporate Officer & Representative Director
Toshio Heike - - Member of Scientific Advisory Board
Tatsutoshi Nakahata - - Member of Scientific Advisory Board
Tsutomu Takeuchi - - Member of Scientific Advisory Board
Makoto Ogawa - - Member of Scientific Advisory Board
Toshio Suda - - Member of Scientific Advisory Board
Shinji Nakao - - Member of Scientific Advisory Board
Robert A. Lewis - - Member of Scientific Advisory Board
Shigetoshi Matsumoto - 2017 Independent Outside Director
Kiyoshi Watanabe 71 2017 Outside Independent Director
Kesao Endo 71 2022 Outside Independent Director
Bruce David Cheson - - Independent Outside Director
Yasuhiro Tamo - 2022 Outside Independent Director
Eiji Ebinuma - - Independent Outside Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4582 Price Commentary

Write your thoughts about SymBio Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email